Trial · NCT03312634
Adverse events222
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 222
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry skin | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 60 | 107 | 95 |
| other | Dry skin | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 37 | 81 | 77 |
| other | Dry skin | Skin and subcutaneous tissue disorders | Untreated (PVO-1A-001) | 0 | 114 | 0 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 19 | 107 | 23 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 21 | 81 | 28 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Untreated (PVO-1A-001) | 0 | 114 | 0 |
| other | Drug eruption | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 15 | 107 | 24 |
| other | Drug eruption | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 26 | 81 | 40 |
| other | Drug eruption | Skin and subcutaneous tissue disorders | Untreated (PVO-1A-001) | 0 | 114 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 19 | 107 | 29 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 14 | 81 | 16 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Untreated (PVO-1A-001) | 0 | 114 | 0 |
| other | Rash | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 25 | 107 | 40 |
| other | Rash | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 11 | 81 | 22 |
| other | Rash | Skin and subcutaneous tissue disorders | Untreated (PVO-1A-001) | 0 | 114 | 0 |
| other | Erythema | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 11 | 107 | 15 |
| other | Erythema | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 16 | 81 | 21 |
| other | Erythema | Skin and subcutaneous tissue disorders | Untreated (PVO-1A-001) | 0 | 114 | 0 |
| other | Skin exfoliation | Skin and subcutaneous tissue disorders | Palovarotene 5 mg | 11 | 107 | 14 |
| other | Skin exfoliation | Skin and subcutaneous tissue disorders | Palovarotene 20/10 mg | 11 | 81 | 23 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03312634/events